{"id":"NCT00264537","sponsor":"Centocor, Inc.","briefTitle":"A Study of the Safety and Efficacy of Golimumab in Subjects With Rheumatoid Arthritis That Are Methotrexate-naive","officialTitle":"A Multicenter, Randomized, Double-blind, Placebo-controlledTrial of Golimumab, a Fully Human Anti-TNFa MonoclonalAntibody, Administered Subcutaneously, in Methotrexate-naive Subjects With Active Rheumatoid Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-12","primaryCompletion":"2008-04","completion":"2012-06","firstPosted":"2005-12-13","resultsPosted":"2009-07-13","lastUpdate":"2014-09-05"},"enrollment":637,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"Placebo injections","otherNames":[]},{"type":"DRUG","name":"Placebo capsules","otherNames":[]},{"type":"DRUG","name":"Methotrexate capsules","otherNames":[]},{"type":"BIOLOGICAL","name":"Golimumab 50 mg injections","otherNames":[]},{"type":"BIOLOGICAL","name":"Golimumab 100 mg injections","otherNames":[]}],"arms":[{"label":"Group 1: Placebo + Methotrexate","type":"EXPERIMENTAL"},{"label":"Group 2: Golimumab 100 mg + Placebo","type":"EXPERIMENTAL"},{"label":"Group 3: Golimumab 50 mg + Methotrexate","type":"EXPERIMENTAL"},{"label":"Group 4: Golimumab 100 mg + Methotrexate","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of golimumab, alone or in combination with methotrexate, as compared to methotrexate alone in rheumatoid arthritis subjects who have not been previously treated with methotrexate.","primaryOutcome":{"measure":"Number of Participants Who Achieved American College of Rheumatology (ACR) 50 Response at Week 24","timeFrame":"Week 24","effectByArm":[{"arm":"Group 1: Placebo + Methotrexate","deltaMin":47,"sd":null},{"arm":"Group 2: Golimumab 100 mg + Placebo","deltaMin":52,"sd":null},{"arm":"Group 3: Golimumab 50 mg + Methotrexate","deltaMin":64,"sd":null},{"arm":"Group 4: Golimumab 100 mg + Methotrexate","deltaMin":58,"sd":null},{"arm":"Combined Golimumab + Methotrexate","deltaMin":122,"sd":null}],"pValues":[{"comp":"OG000 vs OG004","p":"0.053"},{"comp":"OG000 vs OG002","p":"0.042"},{"comp":"OG000 vs OG003","p":"0.177"},{"comp":"OG000 vs OG001","p":"0.521"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":75,"countries":["United States","Argentina","Australia","Austria","Belgium","Canada","Chile","Hungary","India","Malaysia","New Zealand","Philippines","Poland","Russia","Singapore","South Korea","Spain","Taiwan","Thailand","Ukraine","United Kingdom"]},"refs":{"pmids":["27803138","27432355","25005327","23861303","22127693"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":55,"n":172},"commonTop":["Upper Respiratory Tract Infection","Nausea","Bronchitis","Alanine Aminotransferase Increased","Cough"]}}